About 5% of prostate cancer patients have distant metastases at diagnosis. In these metastatic hormone-sensitive prostate cancers (mHSPC), systemic therapy is recommended, according to the guidelines. Moreover, metastasis-directed therapy (MDT) is discussed to prolong survival. The contemporary literature concerning local therapy and MDT in patients with mHSPC is summarized. Selective literature search. In 2018, randomized controlled data on local therapy in mHSPC patients were published by the authors of the STAMPEDE study. Here, patients were randomized between standard of care (SOC) ± radiotherapy to the prostate (RT). Within the overall cohort, no difference regarding 3‑year overall survival (OS) was observed. Within aprespecified subgroup of patients with low metastatic burden. Similar results were observed in numerous retrospective studies analyzing radical prostatectomy; prospective randomized studies are pending. For MDT, there are no sufficient data in mHSPC patients yet. In the current guidelines, systematic therapy is standard of care in mHSPC patients. In patients with low metastatic burden, asurvival benefit was observed when adding percutaneous RT to the prostate. Retrospective studies also suggest abenefit when adding RP. However, whether MDT prolongs survival is still unknown.